Journal of Cancer Therapy
Vol.4 No.11A(2013), Paper ID 40800, 9
pages
DOI:10.4236/jct.2013.411A006
The PARP-1 Inhibitor Olaparib Causes Retention of γ-H2AX Foci in BRCA1 Heterozygote Cells Following Exposure to Gamma Radiation
Emma C. Bourton, Piers N. Plowman, Amanda J. Harvey, Sheba Adam Zahir, Christopher N. Parris
Brunel Institute of Cancer Genetics and Pharmacogenomics, Division of Biosciences, School of Health Sciences and Social Care, Brunel University, Uxbridge, UK
Department of Radiotherapy, St Bartholomew’s Hospital, West Smithfield, London, UK
Brunel Institute of Cancer Genetics and Pharmacogenomics, Division of Biosciences, School of Health Sciences and Social Care, Brunel University, Uxbridge, UK
Brunel Institute of Cancer Genetics and Pharmacogenomics, Division of Biosciences, School of Health Sciences and Social Care, Brunel University, Uxbridge, UK
Brunel Institute of Cancer Genetics and Pharmacogenomics, Division of Biosciences, School of Health Sciences and Social Care, Brunel University, Uxbridge, UK
Copyright © 2013 Emma C. Bourton, Piers N. Plowman, Amanda J. Harvey, Sheba Adam Zahir, Christopher N. Parris et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
E. Bourton, P. Plowman, A. Harvey, S. Zahir and C. Parris, "The PARP-1 Inhibitor Olaparib Causes Retention of γ-H2AX Foci in
BRCA1 Heterozygote Cells Following Exposure to Gamma Radiation,"
Journal of Cancer Therapy, Vol. 4 No. 11A, 2013, pp. 44-52. doi:
10.4236/jct.2013.411A006.